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ContaminantsPharmaceutical compounds were detected at low concentrations in 2.3% of 1231 samples of groundwater
(median depth to top of screened interval in wells=61m) used for public drinking-water supply in California.
Samples were collected statewide for the California State Water Resources Control Board's Groundwater
Ambient Monitoring and Assessment (GAMA) Program. Of 14 pharmaceutical compounds analyzed, 7 were
detected at concentrations greater than or equal to method detection limits: acetaminophen (used as an
analgesic, detection frequency 0.32%, maximum concentration 1.89 μg/L), caffeine (stimulant, 0.24%, 0.29 μg/L),
carbamazepine (mood stabilizer, 1.5%, 0.42 μg/L), codeine (opioid analgesic, 0.16%, 0.214 μg/L), p-xanthine
(caffeine metabolite, 0.08%, 0.12 μg/L), sulfamethoxazole (antibiotic, 0.41%, 0.17 μg/L), and trimethoprim
(antibiotic, 0.08%, 0.018 μg/L). Detection frequencies of pesticides (33%), volatile organic compounds not
including trihalomethanes (23%), and trihalomethanes (28%) in the same 1231 samples were signiﬁcantly
higher. Median detected concentration of pharmaceutical compounds was similar to those of volatile organic
compounds, and higher than that of pesticides.
Pharmaceutical compounds were detected in 3.3% of the 855 samples containing modern groundwater (tritium
activityN0.2 TU). Pharmaceutical detections were signiﬁcantly positively correlated with detections of urban-
use herbicides and insecticides, detections of volatile organic compounds, and percentage of urban land use
around wells. Groundwater from the Los Angeles metropolitan area had higher detection frequencies of
pharmaceuticals and other anthropogenic compounds than groundwater from other areas of the state with
similar proportions of urban land use. The higher detection frequencies may reﬂect that groundwater ﬂow
systems in Los Angeles area basins are dominated by engineered recharge and intensive groundwater pumping.+1 916 278 3071.
litz@usgs.gov (K. Belitz).
 CC BY-NC-ND license.ublished by Elsevier B.V. Open access under CC BY-NC-ND license.P1. Introduction
Pharmaceutical compounds and other anthropogenic organic
compounds are used for many beneﬁcial purposes in modern society,
but commonly constitute contaminants when they are encountered in
the environment (Halling-Sørensen et al., 2002). Pharmaceutical
compounds may enter the environment by many pathways, including
discharge of treated wastewater, seepage from landﬁlls, septic
systems, and sewer lines, and runoff from animal wastes and land
application of manure fertilizers (Glassmeyer et al., 2005; Wu et al.,
2009; Ternes, 1998). Concentrations of individual pharmaceutical
compounds in wastewater treatment efﬂuents generally are less than
1 μg/L, although concentrations as high as several mg/L have been
measured in efﬂuent from treatment plants receiving waste from
pharmaceutical manufacturing facilities (Phillips et al., 2010; Larsson
et al., 2007). Although physical and biological processes occurring inaquatic environments may cause attenuation of many pharmaceutical
compounds, trace concentrations of human and veterinary pharma-
ceutical compounds and metabolites have been detected in surface
water, groundwater, and drinking water (Ternes, 1998; Sacher et al.,
2001; Kolpin et al., 2002; Benotti et al., 2009; Bruce et al., 2010).
Groundwater withdrawals provide approximately 33% of public
water supplies and 98% of domestic water supplies in the U.S. (Kenny
et al., 2009). National reconnaissance studies of the occurrence of
pharmaceutical compounds in groundwater (Barnes et al., 2008a) and
untreated drinking-water sources, including groundwater (Focazio
et al., 2008), targeted sites thought to be susceptible to contamination
from human wastewater and/or animal wastes. These studies
demonstrated that pharmaceutical compounds are indeed present
in groundwater at detectable concentrations and set the stage for
subsequent research: systematic investigation of the distribution of
pharmaceutical compounds in groundwater resources. Studies doc-
umenting detections of pharmaceutical compounds have received
considerable public attention, and public perception of water safety
(based in part on these studies) is likely to affect use of groundwater
resources (Benotti and Snyder, 2009). Therefore, it is important to
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compounds are present in groundwater.
The objective of this study is to systematically evaluate the
distribution of pharmaceuticals in untreated groundwater used for
public drinking-water supplies in California. The study is part of the
California State Water Resources Control Board's Groundwater
Ambient Monitoring and Assessment (GAMA) Program Priority
Basin Project (Belitz et al., 2003). The study is unique for the large
number of sites sampled (1231 for pharmaceuticals), statistically
representative sampling design, comprehensive suite of other water-Fig. 1. Map of 1231 groundwater sites sampled for 14 pharmaceutical compounds for the C
Basin Project, 2004–2010.quality and ancillary data collected on the same samples, and wide
range of hydrologic settings included.
2. Experimental design
2.1. Site selection and sampling
The GAMA Priority Basin Project is a comprehensive assessment of
groundwater quality in aquifers used for public drinking-water supply
in the State of California (Belitz et al., 2003). The Supplementalalifornia Groundwater Ambient Monitoring and Assessment (GAMA) Program Priority
3411M.S. Fram, K. Belitz / Science of the Total Environment 409 (2011) 3409–3417Material contains a detailed description of the project; a summary is
presented here. Groundwater samples for this study were collected
from 1231 sites in California between May 2004 and March 2010 and
analyzed for a broad suite of water quality constituents, including
pharmaceutical compounds (Fig. 1). The sites were located in 28 study
units that represent a reasonably complete sampling of the range of
hydrogeologic conditions and land-use patterns encountered in
California. The study unitswere deﬁned to include the 116 groundwater
basins in the state that account for 95%of thegroundwater use for public
drinking-water supply occurring in groundwater basins (Belitz et al.,
2003).Most of the basins are alluvial basins. Study units included basins
in areas ranging from the heavily urbanized Los Angeles and San
Francisco Bay regions, to dominantly agricultural regions of the Central
Valley between Redding and Bakersﬁeld, to relatively undeveloped
mountainousanddesert regions in theeastern and southeasternparts of
the state. Most agricultural areas in California are extensively irrigated
with surface water or groundwater, and groundwater recharge may be
dominated bypercolationof irrigationwater (for example, Faunt, 2009).
Engineered recharge using stormwater, treated wastewater, or
imported surface water is used in many basins, most notably in the
Los Angeles regionwhere engineered recharge accounts for up to 75% of
the groundwater pumped from the coastal aquifer system (Belitz et al.,
2004; Reichard et al., 2003). Several study units also incorporated areas
outside of groundwater basins that utilize fractured bedrock aquifers.
Detailed descriptions of site selection criteria and sample collection
procedures can be found in USGSData-Series Reports for the study units
(listed in the Supplemental Material). The Data-Series Reports also
contain all of the water-quality data for samples collected in each study
unit. Brieﬂy, each study unit was divided into equal-area grid cells, and
within each cell, one well was randomly selected to represent the cell
(Scott, 1990). This spatially-distributed, randomized well selection
strategy yielded a network of wells that are statistically representative
on an areal basis of the part of the aquifer system used for public
drinking-water supply. Wells were selected primarily from the
population of approximately 16,000 active public drinking-water
supply wells in the database maintained by the California Department
of Public Health (CDPH). The database lists wells used for municipal
supply and wells used for community supply, such as for schools,
campgrounds, and home-owners associations. In cells that had no
accessible CDPH wells, irrigation, domestic, industrial, or monitoring
wells with screened intervals at depths similar to the screened intervals
of CDPH wells in the study unit were sampled. In some study units,
additional, non-grid, wells were sampled to investigate particular
water-quality issues of importance in the study unit. Most of these
wells also were CDPH wells. The 1231 wells sampled for pharmaceu-
ticals included 1000 gridwells and 231 non-gridwells. Themedianwell
depthwas134 m(interquartile range=75mto 198 m)and themedian
depth to the top of the screened interval in the wells was 61 m
(interquartile range=34m to 101 m).
All wells were sampled by the USGS using consistent protocols
(Koterba et al., 1995; U.S. Geological Survey, 2007). To minimize
potential contamination during sample collection, use of products
containing the targeted analytes, including caffeinated beverages,
tobacco, and common non-prescriptionmedications, was discouraged
among ﬁeld personnel. Groundwater to be analyzed for pharmaceu-
ticals was ﬁltered through a 0.3-μm nominal pore size baked glass–
ﬁber ﬁlter during sample collection. Samples were collected in pre-
cleaned and baked, amber glass, 1-L bottles, and shipped on ice via
overnight package service to the USGS National Water Quality
Laboratory (NWQL) in Denver, Colorado for analysis.
2.2. Analytical method for pharmaceutical compounds
The analytical method included fourteen human prescription and
non-prescription pharmaceutical compounds and selected metabolites
(Table 1). These 14 compounds were selected because they are incommonly used prescription or non-prescription products, have
physical properties that suggest potential for persistence in the
environment, and perform acceptably in the chosen analytical proce-
dure (Kolpin et al., 2002). Brieﬂy, pharmaceutical compounds were
extracted from water samples using solid-phase extraction cartridges,
and separated and measured by high-performance liquid chromatog-
raphy with mass spectrometry detection. Cahill et al. (2004) and
Furlong et al. (2008) give detailed descriptions of the analytical
procedures and method performance characteristics.
During the period that samples were analyzed for this study (May
2004 through March 2010), method detection limits (MDL) were
established using several different methods. Initial MDLs were calculated
using the 99-percent conﬁdence interval for 7 replicate analyses of
reagent water spiked with low levels of the compounds made during an
analytical run (U.S. Environmental Protection Agency, 1997; Cahill et al.,
2004; Furlong et al., 2008). These MDLs were used through September
2007. Subsequently, MDLs were evaluated annually using two methods:
the 99-percent conﬁdence interval for 16–24 analyses of low-level spiked
reagent-water samples made over 8–12 month periods (Childress et al.,
1999), and the 99th percentile of the laboratory set blanks analyzed
during the same 8–12 month period (http://bqs.usgs.gov/ltmdl/
background.shtml). These annually determined MDLs were generally
higher than the initial MDLs. In order to compare data from samples
analyzed indifferent years, all datawere censoredusing thehighest of the
MDLs determined for each compound (Table 1). Detections reported by
theNWQLwith concentrations less than the selectedMDLare reported as
bMDL in this study and are not considered detections when calculating
detection frequencies.
Our use of the MDL as the criteria for deﬁning whether a result
reported by the laboratory is considered a detection of the pharmaceu-
tical compound in the groundwater sample (concentration≥MDL) or a
nondetection (concentrationbMDL) is different than the reporting
convention used by some other studies. For the pharmaceutical method
and other analytical methods for organic compounds that use mass
spectrometric detection, laboratories may report results with concen-
trations less than MDLs if the detections met the chromatographic
retention time and mass-spectral pattern criteria for conﬁrmation of
compound identity. Many other USGS studies count results with
concentrations less than the MDL as detections when calculating
detection frequencies (for example, Kolpin et al., 2002; Barnes et al.,
2008a; Focazio et al., 2008). By counting resultswith concentrations less
than MDLs that otherwise met analytical criteria for valid detections as
detections, these studies minimize the probability of “false negative”
results — results that would be reported as nondetections when the
compound is actually present. Such an approach is valid and may be
highly appropriate for research studies whose objective is to survey
what compounds may be present in the environment.
However, given the recent spate of media coverage focused on
occurrence of pharmaceuticals in drinking water and public sensitivity,
we felt it was important to use the MDL as the criteria for deﬁning
detections in this study so that our results would conform to the
meaning of detection as deﬁned for regulatory purposes. TheMDL is the
concentration above which there is more than 99 percent probability
that the measured concentration in the sample is greater than
concentrations measured in blanks, i.e., that the result represents a
detection of the compound present in the environmental sample (U.S.
Environmental Protection Agency, 1997). Results with concentrations
less than the MDL have increased probability of being “false-positive”
detections of the compound in the environmental sample. Of the 550
individual detections of pharmaceutical compounds in groundwater
samples, 484 had concentrations below MDLs.
2.3. Quality assurance and quality control
Evaluation of quality control data is described in detail in the
Supplementary Material, and summarized brieﬂy here. Laboratory set
Table 1
Summary of data for pharmaceutical compounds analyzed in 1231 groundwater samples collected for the California Groundwater Ambient Monitoring and Assessment (GAMA)
Program Priority Basin Project, May 2004 through March 2010.
Compound CASRN a Method detection
limit (μg/L) b
Detection
frequency c
Median detected
concentration (μg/L)
Maximum
concentration (μg/L)
Typical use
Acetaminophen 103-90-2 0.06 0.32% 0.18 1.89 Prescription and non-prescription analgesic and antipyretic
Albuterol 18559-94-9 0.04 nd nd nd Prescription antiasthmatic
Caffeine 58-08-2 0.10 0.24% 0.17 0.29 Non-prescription stimulant (coffee, colas, tea, etc.)
Carbamazepine 298-46-4 0.03 1.46% 0.04 0.42 Prescription mood stabilizer and anticonvulsant
Codeine 76-57-3 0.023 0.16% 0.123 0.214 Prescription analgesic and antitussive
Cotinine 486-56-6 0.019 nd nd nd Metabolite of nicotine (tobacco products)
Dehydronifedipine 67035-22-7 0.04 nd nd nd Metabolite of prescription antianginal and antihypertensive
Diltiazem 42399-41-7 0.04 nd nd nd Prescription antihypertensive and antiarrhythmic
Diphenhydramine 147-25-0 0.02 nd nd nd Non-prescription antihistimine
p-Xanthine 611-59-6 0.06 0.08% 0.12 0.12 Metabolite of caffeine
Sulfamethoxazole 723-46-6 0.08 0.41% 0.16 0.17 Prescription antibiotic
Thiabendazole 148-79-8 0.03 nd nd nd Prescription and veterinary antihelminthic and agricultural antifungal
Trimethoprim 723-70-5 0.017 0.08% 0.018 0.018 Prescription antibiotic
Warfarin 81-81-2 0.05 nd nd nd Prescription anticoagulant
a Chemical Abstracts Service Registry Number.
b Method detection limit (MDL) is the maximum of the up to 5 MDLs used for each compound during the period samples were analyzed. All concentrations reported in units of
microgram per liter (μg/L).
c A total of 1231 groundwater samples were analyzed. Only detections with concentrations greater than or equal to the MDL were considered detections for calculation of
detection frequencies. Compounds not detected reported as “nd”.
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pharmaceutical compounds during laboratory processing and analysis
of groundwater samples. One laboratory blank was processed and
analyzed with each set of 10–16 environmental samples. During the
period samples were analyzed for this study (May 2004 through
March 2010), 691 LSBs were analyzed. The detection frequencies for
the 14 compounds ranged from less than 1% for codeine and warfarin
to 27% for diphenhydramine. Most of the detections in the LSBs had
concentrations less than the MDLs used in this study; however, the
concentrations were similar to those observed in the unscreened set
of groundwater samples. The detection frequencies and concentra-
tions observed in the LSBs analyzed during this study generally were
much higher than those observed during the periods samples were
analyzed for the studies by Kolpin et al. (2002), Focazio et al. (2008),
and Barnes et al. (2008a,b).
Detections in LSBs were not randomly distributed during the
period samples were analyzed for this study. Samples analyzed during
periods with particularly high detection frequencies in the LSBs were
subject to additional quality control screening which resulted in
censoring of some detections of acetaminophen, diphenhydramine,
and thiabendazole with concentrations greater than their respective
MDLs.
Field blanks (FB) were collected at 136 sites between May 2004
and March 2010, and source-solution blanks (SSB) were collected at
77 of those sites. FBs were collected using the same protocols used for
collection of groundwater samples; SSBs were collected at the ﬁeld
site by pouring blank water directly into the sample bottle. FBs assess
potential contamination during sample collection, ﬁeld processing,
shipping, and laboratory processing and analysis; SSBs assess
potential contamination during shipping and laboratory processing
and analysis. The maximum detection frequency for the 13 com-
pounds detected in FBs and the 3 compounds detected in SSBs was
7.4% and 3.9% (both diphenhydramine). The reason the FBs and SSBs
were cleaner than the LSBs is unknown. No additional quality-control
censoring of data was required on the basis of FB detections because
all periods with high detection frequencies in FBs corresponded to
periods with high detection frequencies in LSBs.
2.4. Statistical tests
Non-parametric statistical methodswere used for this study. These
methods are robust techniques that can be used with datasets
containing many nondetections, are generally not affected by outliers,and do not require that the data follow any particular distribution
(Helsel and Hirsch, 2002). The signiﬁcance level (p) used for
hypothesis testing was compared to a threshold value (α) of 5%
(α=0.05) to evaluate whether the relation was statistically signif-
icant (pbα). The Wilcoxon rank-sum test was used to test for
differences between the median values of a parameter in two sets of
samples. Contingency tables were used to test for differences between
detection frequencies in two sets of samples (Helsel and Hirsch,
2002).
3. Results and discussion
3.1. Detections
Of the 1231 groundwater samples analyzed, 28 (2.3%) had
detections ≥MDL of any of the pharmaceutical compounds tested
(data are tabulated in the Supplementary Material). In the same set of
1231 groundwater samples, pesticides and pesticide degradates were
detected in 33% of the samples at concentrations greater than or equal
to the highest MDL used during the period samples were analyzed.
VOCs (solvents, fumigants, gasoline oxygenates, and refrigerants)
were detected in 23% of the samples, and THMs in 28% (Fig. 2). The
prevalence of these 14 pharmaceuticals in aquifers used for public
drinking water supply in California is signiﬁcantly lower than that of
pesticides, VOCs, or trihalomethanes (contingency table tests,
pb0.001).
The detection frequencies of pharmaceutical compounds in
groundwater in this study were lower than the detection frequencies
observed in the national reconnaissance studies of groundwater
(Barnes et al., 2008a), and groundwater used for drinking-water
supplies (Focazio et al., 2008). The national reconnaissance studies
used the same laboratory (NWQL) and analytical methods for
pharmaceutical compounds as used in this study, and for these
comparisons, the detection frequencies in the national reconnaissance
studies were calculated relative to the same MDLs as used in this
study. Of the 25 groundwater samples analyzed by Focazio et al.
(2008), 4 samples had detections of at least one pharmaceutical
compound at concentrations greater than or equal to the MDLs used
in this study. Of the 47 groundwater samples analyzed by Barnes et al.
(2008a), 4 samples had detections of at least one pharmaceutical
compound at concentrations greater than or equal to the MDLs used
in this study. Note that carbamazepine – the compound with the
highest detection frequency in this study and in Focazio et al. (2008) –
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Fig. 2. Detection frequencies and median detected concentrations for pharmaceutical
compounds, pesticides and pesticide degradates, volatile organic compounds (solvents,
fumigants, gasoline oxygenates, and refrigerants), and trihalomethanes in 1231
groundwater samples collected for the California Groundwater Ambient Monitoring
and Assessment (GAMA) Program Priority Basin Project, May 2004 through March
2010.
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detection frequency in this study, 2.3%, is signiﬁcantly lower than the
detection frequencies in the other two studies (contingency table
tests, pb0.001 and p=0.012, respectively).
Differences in strategies used to selected sites for sampling may
explain the lower detection frequencies of pharmaceutical com-
pounds in this study compared to the national reconnaissance studies.
The national reconnaissance studies targeted sites thought to be
susceptible to contamination from human wastewater and/or animal
wastes; whereas, the sites sampled in this study were spatially
distributed over the areal extent of aquifer systems used for public
drinking-water supply and did not speciﬁcally target or avoid areas
with higher (or lower) susceptibility to wastewater contamination.
Of the 14 pharmaceutical compounds analyzed, 7 were detected
above their MDLs in at least one groundwater sample (Table 1):
acetaminophen, caffeine, carbamazepine, codeine, p-xanthine, sulfa-
methoxazole, and trimethoprim. Of the 28 groundwater samples with
detections, 22 had a detection of only one pharmaceutical compound.
Carbamazepine and sulfamethoxazole were the most commonly co-
occurring compounds in the six samples having detection of more
than one compound.3.2. Concentrations
Concentrations of pharmaceutical compounds generally were in
the sub μg/L range: 33 of the 34 detections had concentrations less
than 0.5 μg/L. Median detected concentrations of pharmaceutical
compounds were similar to the median detected concentrations of
VOCs and THMs in the same set of 1231 samples, and higher than the
median detected concentrations of pesticides (Fig. 2). The GAMA
Priority Basin Project (e.g., Landon et al., 2009; Bennett et al., 2010)
and other studies (Toccalino et al., 2004; 2010) put concentrations of
anthropogenic organic compounds in water samples in context
through comparison with regulatory and non-regulatory human-
health-based benchmarks for concentrations in treated drinking
water. However, none of the compounds targeted in this study has
human-health-based benchmarks.One method for putting the concentrations of pharmaceutical
compounds in water into context is to compare them to therapeutic
doses of the compounds (e.g., Richardson and Bowron, 1985; Webb
et al., 2003; Kostich and Lazorchak, 2008). As an example, we compare
the cumulative masses of the compounds that would be consumed
over a lifetime of drinking water containing the highest concentra-
tions measured in this study to typical daily doses of the compounds
[typical daily prescribed doses for acetaminophen, carbamazepine,
codeine, sulfamethoxazole, and trimethoprim (U.S. National Library of
Medicine, 2010), and the amount of caffeine in two cups of coffee for
caffeine and p-xanthine]. The cumulative masses of the 7 compounds
that would be ingested over 70 years of drinking water ranged from
0.5% to 18% of the mass that would be ingested in one typical daily
therapeutic dose. In reality, most concentrations were lower than the
maxima and drinking-water treatment may reduce the concentra-
tions of some pharmaceutical compounds (Benotti et al., 2009), thus
these may be maximum estimates of potential exposure.
Bruce et al. (2010) developed screening levels for 15 pharmaceu-
tical compounds based on animal toxicity data and adverse effects on
human health at therapeutic doses, and found that the equivalent
concentrations in drinking water corresponding to those screening
levels were factors of 102 to 107 higher than the maximum
concentrations detected in drinking water. The equivalent concen-
trations in drinking water corresponding to the screening levels for
the three compounds detected in this study, carbamazepine,
sulfamethoxazole, and trimethoprim, were factors of 30, 105 and
4×105, respectively, higher than the maximum concentrations
detected in this study. Bruce et al. (2010) concluded that exposure
to the 15 compounds in drinking water is unlikely to have adverse
effects on human health; however, the potential effects of exposure to
other pharmaceutical compounds or to mixtures, and the potential
effects on sensitive populations remain unknown. Other studies have
similarly concluded that there is no well-established body of evidence
linking exposure to the low concentrations of pharmaceutical
compounds found in drinking water to short-term or long-term
deleterious effects on human health (Khetan and Collins, 2007).
Evidence is emerging that chronic exposure to low concentrations
of some pharmaceutical compounds may have deleterious effects on
aquatic ecosystems. Although most of the biota examined have been
surfacewater species and thus unlikely to be exposed to groundwater,
comparison between concentrations observed to affect aquatic
ecosystems and concentrations detected in groundwater may help
put the magnitude of the measured concentrations in context. The
lowest concentration at which chronic effects have been observed
generally are in the range of 10 μg/L to 300 μg/L (Crane et al., 2006;
Carlsson et al., 2006; Fent et al., 2006), concentrations that are factors
of 10 to 104 higher than the maximum concentrations reported in this
study. However, as more data are gathered on additional compounds,
effects at even lower concentrations are being observed, such as
alteration of aquifer bacteria growth and community composition by
exposure to sulfamethoxazole at concentrations as low as 1.4 μg/L
(Underwood et al., 2011) and changes in behavior of marine
amphipods by exposure to ﬂuoxetine (an antidepressant) at concen-
trations as low as 0.1 μg/L (Guler and Ford, 2010). Synthetic estrogens,
a pharmaceutical class not analyzed in this study, can have dramatic
and alarming effects on ﬁsh at concentrations less than 0.01 μg/L
(Kidd et al., 2007). In addition, data indicate that some pharmaceu-
tical compounds have additive effects, thus mixtures must also be
considered (Pomati et al., 2006, 2008).
3.3. Behavior of individual pharmaceutical compounds
The 14 compounds investigated in this study – half of which were
detected and half of which were not – have a number of properties that
may explain which compounds were detected in groundwater and
which were not. Carbamazepine was the most frequently detected
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widely used because of its multiple therapeutic applications (Table 1).
The maximum concentration detected, 0.42 μg/L, was similar to
maximum concentrations detected in groundwater in other studies
(Drewes et al., 2003; Sacher et al., 2001; Focazio et al., 2008; Godfrey
et al., 2007; Rabiet et al., 2006).
As noted previously, carbamazepine is among the most frequently
detected pharmaceutical compounds in groundwater both in the United
States and in other countries. The greater detection frequency of
carbamazepine compared to other compounds with much higher use
(e.g., acetaminophen and caffeine) reﬂects the recalcitrant nature of the
molecule. Laboratory experiments and ﬁeld studies indicate that
carbamazepine is not noticeablydegraded and suffers little orno sorption
in water-sediment systems (Löfﬂer et al., 2005; Drewes et al., 2003;
Snyder et al., 2004; Heberer et al., 2004), and that it is highly resistance to
biodegradation (Clara et al., 2004; Suarez et al., 2010;Wuet al., 2010). It is
resistant to hydrolysis (Lam et al., 2004) and its' molecular structure
suggests that it exists as a neutral molecule at environmental pHs,
resulting in limited interaction with the generally negatively-charged
mineral surfaces in aquifer materials. These properties indicate that
carbamazepine should be highly persistent in groundwater.
Acetaminophen, caffeine, and sulfamethoxazole were the next
most frequently detected pharmaceutical compounds in this study.
Acetaminophen and caffeine are relatively frequently detected in
surface water (e.g., Kolpin et al., 2002), have much higher use than
carbamazepine, but have chemical properties that make them less
persistent in groundwater. In studies examining the differential levels
of caffeine and acetaminophen in wastewater and in nearby
groundwater, both are strongly attenuated by passage through
aquifer materials (Löfﬂer et al., 2005; Drewes et al., 2003; Snyder
et al., 2004; Godfrey et al., 2007), likely because both biodegrade
relatively rapidly (Benotti and Brownawell, 2009; Yu et al., 2006;
Bradley et al., 2007). Sulfamethoxazole generally is minimally
attenuated by passage through aquifer materials (Godfrey et al.,
2007; Snyder et al., 2004; Sacher et al., 2001; Barber et al., 2009), and
is nearly as resistant to biodegradation as carbamazepine (Benotti and
Brownawell, 2009; Snyder et al., 2004; Suarez et al., 2010).
Seven compounds were not detected in groundwater samples in
this study: albuterol, cotinine; dehydronifedipine, diltiazem, diphen-
hydramine, thiabendazole, and warfarin, and three were detected in
less than 0.2% of samples: codeine, p-xanthine, and trimethoprim. The
absence of these ten compounds likely reﬂects a combination of
physical properties and source patterns. Albuterol, codeine, dehy-
dronifedipine, diltiazem, and warfarin are rarely present in surface
water at concentrations greater than the MDLs used in this study
(Kolpin et al., 2002; Focazio et al., 2008), suggesting that they may be
highly biodegradable and therefore unlikely to occur in groundwater.
Cotinine, codeine, p-xanthine, trimethoprim, and warfarin undergo
signiﬁcant attenuation between wastewater sources and adjacent
groundwater as the water passes through aquifer materials (Godfrey
et al., 2007).
Albuterol, diltiazem, and nifedipine (the parent compound of
dehydronifedipine) were all ﬁrst approved by the USFDA in 1981 (U.S.
Food and Drug Administration, 2010). The other 11 compounds were
either approved for use before 1950 or are found in non-prescription
substances that have been in use for centuries (i.e., tobacco,
caffeinated beverages). Most of the wells in this study are long-
screened public-supply wells tapping groundwater with a range of
ages, and are relatively deep (median depth=119 m, median depth
to top of screen=52 m for wells containing tritium ≥0.2 TU). The
depths of these wells suggest that the fraction of very young
groundwater (recharged since 1981) is likely to be small. Thus, it is
unlikely that compounds not in use until 1981 would exist in samples
from these wells at detectable levels.
Diphenhydramine and thiabendazole have not been commonly
measured in previous studies. There is therefore little information onthe potential for biodegradability of either compound. In laboratory
microcosm experiments examining degradation of pharmaceutical
compounds in soils amendedwith biosolids, diphenhydramine was as
resistant to degradation as carbamazepine (Wu et al., 2010). This
ﬁnding suggests that a process other than biogradation may be
responsible for diphenhydramine not being detected in groundwater.
3.4. Relations to water quality, well depth, and land use
The previous section described ﬁndings in regards to the speciﬁc
pharmaceutical compounds that were found in a small number of the
1231 groundwater sites tested. Equally important ﬁndings arise from
an examination of the relations between the occurrence of pharma-
ceutical compounds and other water-quality constituents and
potential explanatory factors, such as well depth and land use.
Occurrence of pharmaceutical compounds was found to be
strongly correlated with the presence of modern water and with
occurrence of other anthropogenic compounds. Groundwater samples
with tritium activities greater than 0.2 TU contain at least some
modern water (water recharged since 1952). [Natural background
tritium levels in precipitation were approximately 5 TU prior to 1952
when atmospheric nuclear bomb testing began (Craig and Lal, 1961);
groundwater recharged in 1950 with an initial tritium activity of 5 TU
would have a tritium activity of less than 0.2 TU when the wells were
sampled in 2004–2010.] Most of the wells had long screened intervals
and thus the groundwater samples were mixtures of water of a wide
range of ages. All 28 groundwater samples with detections of
pharmaceutical compounds had tritium activities greater than 0.2
TU, indicating presence of at least some modern groundwater.
Total pesticide, total VOC (except THMs), and total THM
concentrations in the 28 groundwater samples with detections of
pharmaceutical compounds were signiﬁcantly greater than median
concentrations in the 839 samples containing at least some modern
water and no detections of pharmaceutical compounds (Fig. 3a;
Wilcoxon rank-sum test pb0.001). Also, both sets of samples
containing at least some modern water had signiﬁcantly greater
median concentrations of pesticides, VOCs, and THMS than the 360
samples containing no modern water (Fig. 3a; Wilcoxon rank-sum
test pb0.001). These correlations demonstrate that the well sites that
produced samples with detectable levels of pharmaceuticals are also
affected by other anthropogenic activities.
Of the 28 samples with detections of pharmaceutical compounds,
86% also contained pesticides at concentrations greater than the
highestMDL used during the period of study, 71% also contained VOCs
other than THMs (primarily solvents), and 61% also contained THMs.
The types of pesticides detected in the samples with detections of
pharmaceutical compounds suggest urban, rather than agricultural,
sources. Among the 23 samples with detections of pesticides and
pharmaceutical compounds, 74% had detections of prometon, 3,4-
dichloraniline (degradate of diuron), or tebuthiuron, herbicides used
in urban settings (rights-of-way and landscaping) in California
(Kegley et al., 2005), and 30% had detections of ﬁpronil (or its
degradates), an insecticide used for structural pest control and in pest
control products for pets. The detection frequencies of these three
urban-use herbicides and of ﬁpronil, 24% and 0.3%, respectively, were
signiﬁcantly lower in the 353 samples with detections of pesticides
and not pharmaceuticals (contingency table tests, pb0.001).
If pharmaceutical compounds in the groundwater samples
primarily were associated with recharge of treated wastewater, then
one might expect that the occurrence of pharmaceuticals would be
most strongly linked to occurrence of THMs, because THMs generally
are formed during the disinfection step of wastewater treatment.
However, in these data, the occurrence of pharmaceuticals is more
strongly associated with occurrence of pesticides (contingency table
test, p=0.035). This may reﬂect the physical properties of the
compounds. None of the 14 pharmaceutical compounds tested are
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pounds are more similar to pesticides than to THMs and many other
VOCs, thus, the transport of pharmaceutical compounds in aquifer
systems may more closely resemble that of pesticides.
Occurrence of pharmaceutical compounds in groundwater was not
correlated with well depth or with depth to the top of the screened
interval in the well. The median depth and depth to top of screen for
wells with detections of pharmaceutical compounds (126 m and
55 m, respectively), were not signiﬁcantly different than the medians
for wells with evidence for modern water and no detections of
pharmaceutical compounds (119 m and 53 m, respectively) (Fig. 3b).
Barnes et al. (2008a) found that groundwater samples from shallower
wells had signiﬁcantly greater numbers of different wastewater
indicator compounds (including pharmaceuticals) detected, com-
pared to deeper wells. This differential ﬁnding may arise from the
contrast in well selection strategies and well depths. Barnes et al.
(2008a) targeted wells in areas with suspected sources of wastewater
at the surface, and the wells were relatively shallow (median depth
19 m). Under those conditions, occurrence of pharmaceutical com-
pounds may decrease with depth because increased travel distance
from the surface source likely results in greater attenuation. Well
selection for this study was not targeted to areas with suspected
surface sources, thus, no correlation between well depth and
occurrence was expected.
Occurrence of pharmaceutical compounds in groundwater was
also found to be correlated with land use. Previous studies have
demonstrated that land use in a 500-meter buffer around a well site is
a useful predictor of occurrence of VOCs in groundwater (Johnson and
Belitz, 2009). Land use classes from the nationwide USGS National
Land Cover Dataset (Nakagaki et al., 2007) were consolidated into 3
groups: urban, agricultural, and undeveloped land uses. The percent-
age of urban land use around well sites with detections of
pharmaceutical compounds and evidence for presence of modern
water was signiﬁcantly greater than the percentages of urban land use
around well sites with no detections of pharmaceutical compounds
and evidence for presence (Wilcoxon rank sum test p=0.035) or
absence (Wilcoxon rank sum test p=0.017) of modern water
(Fig. 3c). Occurrence of pharmaceutical compounds was not signif-
icantly correlated with agricultural land use.
Half of the groundwater samples with detections of pharmaceu-
tical compounds are from the Los Angeles metropolitan area. This
primarily reﬂects the fact that the Los Angeles area is the largest
urbanized area in the state. The median percentage of urban land use
at sites with samples containing somemodern groundwater in the Los
Angeles area was 79%, while that of sites with samples containing
some modern groundwater in the rest of the study (7%) was
signiﬁcantly lower (Wilcoxon rank-sum test pb0.001).
The higher amount of urbanization in the Los Angeles area,
however, does not account entirely for the greater detection
frequency of pharmaceutical compounds. Wells in the Los Angeles
area showed higher detection frequencies of pharmaceuticals than
wells in other parts of the state, even when the data were normalized
for the degree of urban land use. Over nearly the entire range of urban
land-use percentages, the Los Angeles area groundwater from wells
containing some modern groundwater has greater detection frequen-
cies of pharmaceuticals, pesticides, VOCs, and THMs than groundwa-
ter containing some modern groundwater from other areas of the
state (Fig. 4abc). The greater detection frequency also is not due toFig. 3. Box plots of A) concentrations of pesticides, VOCs (other than THMs), and
trihalomethanes and B) depth to top of screened interval in well, well depth, and
percentage of urban land use within 500 m of the well site for 1231 groundwater
samples also analyzed for pharmaceutical compounds and tritium activity for the
California Groundwater Ambient Monitoring and Assessment (GAMA) Program Priority
Basin Project, May 2004 through March 2010. Samples divided into three categories on
the basis of presence or absence of detections of pharmaceutical compounds and
tritium activity greater than or less than 0.2 TU.
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and detection frequencies of pharmaceutical compounds, pesticides and pesticide
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into groups of 20 (Los Angeles) or 40 (other areas) for calculations of average land use
and detection frequencies of classes of organic compounds.
3416 M.S. Fram, K. Belitz / Science of the Total Environment 409 (2011) 3409–3417wells being shallower than they are in other urbanized areas in the
state: among all wells with greater than 50% urban land use and
containing some modern water, wells in the Los Angeles area have
signiﬁcantly greater depths to the tops of the screened intervals
(91 m) than do wells in the rest of the state (53 m) (Wilcoxon rank-
sum test pb0.001).
The greater detection frequencies of pharmaceuticals and other
anthropogenic organic compounds in Los Angeles area groundwater
may be related to the highly engineered nature of the groundwater
ﬂow systems in many of the Los Angeles area groundwater basins.These ﬂow systems are driven by engineered recharge, the use of
treated wastewater and storm water for recharge, and signiﬁcant
amounts of groundwater pumping (Belitz et al., 2004; Dawson et al.,
2000; Shelton et al., 2000). Inﬁltration basins for recharge of storm
water and river baseﬂow (primarily treated wastewater) have been in
use since the 1920s in some areas and this artiﬁcially-recharged
groundwater has been drawn laterally across the basins by intensive
groundwater pumping down-gradient from the recharge facilities.
Artiﬁcial recharge accounts for up to 75% of the groundwater pumped
from the coastal aquifer system (Belitz et al., 2004; Reichard et al.,
2003). This ﬂow systemmay serve to transport anthropogenic organic
constituents from the surface into the aquifer system much more
efﬁciently than in other urbanized areas of the state that do not use
artiﬁcial recharge as intensively.
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